

# Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

NCT07011810

---

|                   |                               |
|-------------------|-------------------------------|
| <b>Status</b>     | RECRUITING                    |
| <b>Phase</b>      | Phase 2                       |
| <b>Sponsor</b>    | Fred Hutchinson Cancer Center |
| <b>Enrollment</b> | 50 participants               |

## Key Eligibility Criteria

---

### Inclusion (19)

- Adults aged 18 and older
- Ability to understand and willingness to sign a written informed consent document
- Allogeneic stem cell transplant, with active cGVHD requiring systemic treatment. Active cGVHD is defined as the presence of signs and symptoms of cGVHD diagnosed per the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical trials in cGVHD
- Sclerotic skin score 2-3 or PROM  $\leq$  24 due to cGVHD
- Initial diagnosis of sclerosis within the past 24 weeks (168 days)

... and 14 more (see full listing online)

### Exclusion (14)

- Hospitalization for evaluation or management of an infection within 28 days prior to screening
- History or other evidence of significant organ dysfunction that would make the patient, in the opinion of the investigator, unsuitable for the study
- On more than 1 mg/kg/day prednisone or prednisone equivalent
- History of non-compliance
- History or other evidence of uncontrolled psychiatric illness that that would limit compliance with study requirements

... and 9 more (see full listing online)

## Locations (3 total)

---

Moffitt Cancer Center, Tampa, Florida, United States

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States